• Concanamycin A: V-type H+-ATPase Inhibitor for Cancer Resear

  2026-06-12

  Concanamycin A is a gold-standard V-type H+-ATPase inhibitor, enabling researchers to dissect endosomal acidification and apoptosis in cancer models with precision. This article unpacks advanced workflows, troubleshooting strategies, and the latest findings on metabolic stress modulation, making it a practical guide for translational cancer biology labs.

• Rapid Purification of Annexin V for Biophysical Analysis

  2026-06-12

  This study introduces a streamlined protocol for the purification of recombinant annexin V, leveraging mild cell lysis and calcium-mediated liposome binding for high purity. The approach removes common contaminants rapidly, facilitating structural and functional studies of annexin V and supporting advanced biophysical research.

• Dibutyryl-cAMP, Sodium Salt: Precision Control of cAMP Pathw

  2026-06-11

  Explore how Dibutyryl-cAMP, sodium salt enables next-generation cAMP signaling pathway research through selective PKA activation and sustained intracellular effects. This in-depth article uncovers unique mechanistic insights and advanced applications beyond basic protocol optimization.

• Lopinavir (ABT-378): Protocol Mastery for HIV & Antiviral As

  2026-06-11

  Lopinavir (ABT-378) from APExBIO stands out as a robust solution for HIV protease inhibition and emerging antiviral research. This guide delivers actionable workflows, optimization strategies, and cross-pathogen insights to advance both classic HIV and novel coronavirus studies.

• Propranolol: Non-Selective β-Blocker for Translational Resea

  2026-06-10

  Propranolol, a non-selective β-adrenergic receptor blocker, enables reproducible cardiovascular, neurobehavioral, and metabolic research. APExBIO's high-purity Propranolol optimizes experimental workflows and empowers advanced troubleshooting in both in vitro and in vivo models.

• Fulvestrant (ICI 182,780): Optimizing ER Antagonism in Bench

  2026-06-10

  Fulvestrant (ICI 182,780) stands out as a gold-standard ER antagonist, uniquely enabling robust workflows for apoptosis induction, endocrine therapy resistance modeling, and chemosensitization in breast cancer studies. This guide translates the latest mechanistic insights and troubleshooting strategies into actionable protocols for maximizing experimental reproducibility.

• Fumagillin for Angiogenesis and Antiparasitic Research Workf

  2026-06-09

  Fumagillin stands out as a dual-purpose methionine aminopeptidase-2 inhibitor, enabling precise angiogenesis pathway studies and robust antiparasitic assays. This article translates new in vitro and in vivo findings into clear, actionable protocols and troubleshooting guidance for cancer research and beyond.

• Scenario-Driven Solutions with Cell Counting Kit-8 (CCK-8)

  2026-06-09

  This article provides practical, evidence-backed guidance for biomedical researchers and laboratory technicians facing common challenges in cell proliferation and cytotoxicity assays. Drawing on real-world scenarios, we demonstrate how Cell Counting Kit-8 (CCK-8), SKU K1018, delivers reproducible, sensitive cell viability measurement and workflow advantages for cancer research and beyond.

• Verteporfin in Photodynamic Therapy: Experimental Workflows

  2026-06-08

  Verteporfin, known as CL 318952, is redefining photodynamic therapy by combining potent light-activated vascular occlusion with unique autophagy inhibition. This article details practical protocols, advanced applications in age-related macular degeneration research, and actionable troubleshooting insights, spotlighting APExBIO's Verteporfin as a versatile tool for translational studies.

• Y-27632 in Translational Research: Strategic Cytoskeletal Co

  2026-06-08

  This thought-leadership article explores the mechanistic underpinnings and strategic deployment of Y-27632, a selective ROCK inhibitor, in translational research. We bridge foundational insights into cytoskeletal modulation with emerging applications in stem cell biology, cancer, and disease modeling, drawing on recent evidence and best-in-class protocols to provide actionable, evidence-backed guidance.

• SP2509 (SKU B4894): Reliable LSD1 Antagonism for AML Researc

  2026-06-07

  This article explores how SP2509 (SKU B4894), a potent Lysine-specific demethylase 1 antagonist from APExBIO, addresses common laboratory challenges in acute myeloid leukemia (AML) epigenetics research. Scenario-driven Q&As provide evidence-based guidance on protocol optimization, data interpretation, and product selection, ensuring reproducibility and translational impact.

• 2X HyperFusion High-Fidelity Master Mix: Precision PCR for C

  2026-06-06

  Unlock unparalleled accuracy in cloning and immunogenomic research with the 2X HyperFusion High-Fidelity Master Mix. This advanced solution empowers researchers with robust, error-minimized PCR workflows, ideal for CRISPR applications and high-stakes molecular cloning, as demonstrated by emerging breakthroughs in cancer immunotherapy.

• Sisomicin, Netilmicin, and Dibekacin: Comparative Antibacter

  2026-06-05

  This review evaluates the antibacterial spectrum, resistance mechanisms, and clinical utility of sisomicin, netilmicin, and dibekacin. It highlights sisomicin’s superior in vitro activity against Pseudomonas aeruginosa compared to gentamicin, the semi-synthetic modifications of netilmicin and dibekacin that overcome certain resistance pathways, and draws attention to their pharmacokinetic and toxicity profiles. The findings guide researchers in selecting aminoglycoside antibiotics for infection models, with implications for both Gram-negative and Gram-positive bacterial research.

• ISRIB (trans-isomer): A Selective PERK Inhibitor in ER Stres

  2026-06-05

  ISRIB (trans-isomer) is a potent, selective PERK inhibitor that reverses eIF2α phosphorylation and restores protein synthesis under ER stress. This compound stabilizes eIF2B dimers and inhibits ATF4 translation, demonstrating efficacy in cellular and in vivo models of cognitive impairment. Its utility in ER stress research and memory studies is supported by recent peer-reviewed findings.

• ICOS Signaling and Th2 Differentiation in Allergic Rhinitis

  2026-06-04

  This study establishes that inducible co-stimulator (ICOS) signaling directly influences the differentiation and prevalence of Th2 cells in allergic rhinitis (AR), highlighting ICOS-expressing Th2 cells as a potential therapeutic target. Functional experiments reveal that manipulating ICOS and the PI3K-Akt-mTOR pathway alters Th2 cell levels, with implications for improving allergen immunotherapy outcomes.

454 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page